Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.54 |
| ▸ | AKT1 | P31749 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668648 | 0.84 | TACR1 (0.67) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL4990397 | 0.82 | SCN4A (0.63) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19686194 | 0.79 | SCN4A (0.58) | SCN4AAKT1TACR1CDK7CDK2 | |
| SCHEMBL875373 | 0.76 | MRGPRX4 (0.47) | — | |
| SCHEMBL19686203 | 0.75 | SCN4A (0.57) | SCN4AAKT1TACR1CACNA1FCACNA1D | |
| SCHEMBL19686722 | 0.74 | SCN4A (0.55) | SCN4AAKT1TACR1CACNA1FCACNA1D | |
| SCHEMBL19668462 | 0.74 | TACR1 (0.53) | SCN4AAKT1TACR1CACNA1FCACNA1D | |
| SCHEMBL2394573 | 0.74 | SCN4A (0.69) | SCN4AAKT1 | |
| SCHEMBL19686108 | 0.74 | SCN4A (0.69) | SCN4AAKT1 | |
| SCHEMBL19686114 | 0.72 | SCN4A (0.47) | SCN4AAKT1TACR1CACNA1FCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885AKT1 1612/4885TACR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.